D3 partial agonist
D3 dopamine receptor partial agonist
- Modulates reward/motivation signaling
- May improve negative and cognitive symptoms
- Can cause compulsive behaviors
- Possible cognitive benefit and ↓ negative symptoms
- Possible improvement of mood and motivation
- Possible contribution to akathisia (secondary to D2)
Drugs with this mechanism (11)
- Aripiprazole — D2 partial agonist; weight-favorable, activating, low prolactin; can cause akathisia.
- Aripiprazole lauroxil LAI — Long-acting aripiprazole prodrug injection for schizophrenia; requires a loading strategy.
- Aripiprazole lauroxil LAI — Rapid-start aripiprazole lauroxil injection used only to initiate Aristada treatment.
- Aripiprazole monohydrate LAI — Extended-interval aripiprazole LAI for schizophrenia and bipolar maintenance.
- Aripiprazole monohydrate LAI — Long-acting aripiprazole for schizophrenia and bipolar maintenance; akathisia remains prominent.
- Brexpiprazole — D2 partial agonist similar to aripiprazole but less activating.
- Cariprazine — D3-preferring dopamine partial agonist for schizophrenia, bipolar disorder, and adjunctive depression.
- Dehydroaripiprazole — Aripiprazole's long-lived active metabolite, with the same D2 partial agonism and a large share of steady-state exposure.
- Desmethylcariprazine — Cariprazine metabolite with the same D3-preferring partial agonism as the parent.
- Didesmethylcariprazine — Cariprazine's long-lived second metabolite — the reason steady state takes weeks and washout takes longer.
- Norclozapine — Active clozapine metabolite; M1 agonist implicated in some clozapine effects.
All mechanisms · Open D3 partial agonist in the interactive console ↗